R&D day (replay & slides)

 

 

selected press releases

24 April 2008
Addex Starts ADX10059 Phase I Formulation Selection Study read more

18 April 2008
Laurent Massuyeau Appointed Head of Business Development read more

18 April 2008
Ray Hill Elected to Board, All Board Proposals Passed at 2008 AGM read more

26 February 2008
Addex Full Year 2007 Financial Results read more

3 January 2008
Addex and Merck & Co., Inc. Collaborate to Develop Drugs for Schizophrenia read more

meet Addex

Addex will be attending the events listed here

Addex Pharmaceuticals discovers and develops allosteric modulators, a different kind of small molecule therapeutic agent. Allosteric modulation may offer more sophisticated ways to normalize biological signaling perturbed by disease compared to classical “orthosteric” agonist or antagonist drugs. Addex' goal is to grow into a world class pharmaceutical group by leveraging its expertise in this emerging class of drugs.

 

investors

In May 2007, Addex completed an initial public offering on the SWX Swiss Exchange, raising CHF137 million ($111 million / €83 million). Click here for stock quote & more.